Clinical Profile of Patients and Antibiogram of Acinetobacter baumannii Isolates in a Tertiary Care Hospital, Central India

Acinetobacter baumannii (A. baumannii) is a remarkable opportunistic pathogen responsible for a great proportion of hospital-associated infections and the high prevalence of resistance towards many classes of antibiotics makes the treatment challenging. The present cross-sectional study was conducted in the Department of Microbiology, IMCHRC, Indore. The study was approved by IEC and conducted from October 2019 to September 2021. A total number of 168 Acinetobacter species including 143 A. baumannii were isolated from the various clinical specimens, the majority of the isolates were obtained from the respiratory system (66%), followed by urine, pus/wound swab, blood, fluids and other samples. The majority of the patients who had underlying/diagnosed with a disease such as aspiration pneumonia/pneumonia (35%), cerebrovascular accident/haemorrhagic shock (30.7%), respiratory failure (24%), accelerated HTN/HTN(18%), and less common were septicemia (8.4), acute kidney injury/chronic kidney diseases (7.7%) and trauma/burns (5.5%). The antibiotic susceptibility testing showed higher antibiotic resistance to cefotaxime (94%), ceftazidime (93%), cefepime (92%), imipenem (92%), meropenem (90%) and the resistance was low to doxycycline (39%) Polymyxin B (8%). The association between antibiotic resistance and the clinical profile of patients was found significant (p-value < 0.05). In our study, a remarkably high antibiotic resistance pattern was observed in the classes of antibiotics in A. baumannii isolates, mostly MDR and XDR. To address infection caused by antibiotic-resistant A. baumannii, appropriate antibiotic administration in a clinical setting is essential. Moreover, local and national surveillance data, stringent infection control, and antimicrobial stewardship are required.